IC Targets AS filed a new patent application on improved detection of heart disease

IC Targets AS announced filing of a new patent application for use of the MRI contrast agent mangafodipir. The application describes a novel method for detecting abnormal levels of proteins in the heart, especially those linked to fibrosis and amyloidosis.

These conditions can cause damaging changes in heart tissue. Fibrosis increases the risk of heart failure and irregular heart rhythms. Earlier and more precise detection allows doctors to better assess a patient’s risk and determine whether specialized treatment is needed.

Improved detection of these conditions will also increase demand for MRI examinations, which help doctors evaluate how much and where the heart is affected.

“This new patent application marks an important step in IC Targets’ efforts to develop better tools for diagnosing heart disease and supporting earlier, more accurate treatment,” said Jonny Østensen, Chief Scientific Officer.

The application strengthens the company’s expanding patent portfolio, which includes several innovative methods aimed at advancing cardiac diagnostics and patient care.